Affiliations: [a] Cellular and Molecular Research Center, Zahedan University of Medical Sciences, Zahedan, Iran | [b] Department of Clinical Biochemistry, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran | [c] Urology and Nephrology Research Center, Department of Urology, Shahid Labbafinejad Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran | [d] Genetics of Non Communicable Disease Research Center, Zahedan University of Medical Sciences, Zahedan, Iran
Correspondence:
[*]
Corresponding author: Mohammad Hashemi, Department of Clinical Biochemistry, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran. Tel.: +98 5433295791; Fax: +98 5433295796; E-mail:[email protected]; [email protected]
Abstract: The association studies between miR-34b/c rs4938723 polymorphism and cancer
risk showed conflicting results. This study aimed to assess the impact of
rs4938723 polymorphism on prostate cancer risk. This case-control study was
done on 151 prostate cancer (PCa) patients and 152 benign prostate
hyperplasia to examine whether rs4938723 polymorphism in the promoter of
pri-miR-34b/c was linked to the carcinogenesis of PCa in a sample of Iranian
population. Genotyping of Pri-miR-34 b/c rs4938723 polymorphism was
performed by using polymerase chain reaction restriction fragment length
polymorphism (PCR-RFLP) method. The results showed that rs4938723 variant
significantly increased the risk of PCa in codominant (OR = 1.92, 95% CI =
1.15 - 3.18, p= 0.012, TC vs TT), dominant (OR = 1.99, 95% CI = 1.23 - 3.24,
p= 0.005, TC + CC vs TT), and allelic (OR = 1.79, 95% CI = 1.20 - 2.68, p= 0.005, C
vs T) inheritance model. Our findings propose that Pri-miR-34 b/c rs4938723
variant may be a risk factor for the development of PCa in a sample of
Iranian population. Larger sample sizes with different ethnicities are
required to validate our findings.
